


FIGURE: 1a




FIGURE: 1b




FIGURE: 2a




FIGURE: 2b




FIGURE: 3a




FIGURE: 3b




FIGURE: 4a




FIGURE: 4b




FIGURE: 4c




FIGURE: 4d




FIGURE: 5a




FIGURE: 5b




FIGURE: 6a




FIGURE: 6b




FIGURE: 7a




FIGURE: 7b




FIGURE: 8a




FIGURE: 8b




FIGURE: 9a




FIGURE: 9b




FIGURE: 10a




FIGURE: 10b




FAC.009/EACI-41 9 Hybridomas: ELISA IgGtotal
O.D. at O/N reading
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
5E6
5F10
6G8
4H6
8H8
5D10
7C2
6B7
3D11
medium
Clone
pTau peptide T9.5
tau peptide T9.6
total pTau yeast
total Tau E. Coli
BSA

FIGURE: 10c


FAC002/E ACI-41 Hybridomas: ELISA screening
O.D. absorvance
3,5
3
2,5
2
1,5
1
0,5
0
1A10
1B8
1F7
2A9
2D6
2G6
3D12
4B6
7G12
8C2
9A9
9B11
9C2
9C5
9D3
9F1
9F3
9G1
9G9
10A4
10G3
Clone
T8
T9
hP-Tau



FAC002/E ACI-41 Hybridomas: ELISA screening
O.D. absorvance
3,5
3
2,5
2
1,5
1
0,5
0
1B10
1C9
1C10
1F7
2D7
3A6
3B9
4A6
4B12
5B1
5C4
5D1
5G6
6G1
6G11
7E1
7F4
8E9
9C2
9C12
9D3
9F1
9F3
9F4
9H3
Clone
T8
T9
hP-Tau

FIGURE:11





FIGURE: 12

a.



b.




FIGURE: 13



ACI-35-EPFL-017 anti-Tau393-408 [pS396/pS404] IgG
O.D. at 1/100 dilution
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
d-7
d7
d21
d35
d56
ACI-35; Process L3 ACI; i.p.
ACI-35; Process L3 ACI; s.c.
ACI-35; Process A ACI; i.p.
ACI-35; Process A ACI; s.c.

FIGURE: 14



ACI-35-EPFL-017 anti-Tau393-408 [pS396/pS404] IgG1
O.D. at 1/1600 dilution
2.500
2.000
1.500
1.000
0.500
0.000
ACI-35; Process L3 ACI; i.p.
ACI-35; Process L3 ACI; s.c.
ACI-35; Process A ACI; i.p.
ACI-35; Process A ACI; s.c.
ACI-35-EPFL-017 anti-Tau393-408 [pS396/pS404] IgG2a
O.D. at 1/3200 dilution
3.000
2.500
2.000
1.500
1.000
0.500
0.000
ACI-35; Process L3 ACI; i.p.
ACI-35; Process L3 ACI; s.c.
ACI-35; Process A ACI; i.p.
ACI-35; Process A ACI; s.c.
ACI-35-EPFL-017 anti-Tau393-408 [pS396/pS404] IgG2b
O.D. at 1/3200 dilution
4.000
3.500
3.000
2.500
2.000
1.500
1.000
0.500
0.000
ACI-35; Process L3 ACI; i.p.
ACI-35; Process L3 ACI; s.c.
ACI-35; Process A ACI; i.p.
ACI-35; Process A ACI; s.c.
ACI-35-EPFL-017 Tau393-408 [pS396/pS404] IgG3
O.D. at 1/800 dilution
3.000
2.500
2.000
1.500
1.000
0.500
0.000
ACI-35; Process L3 ACI; i.p.
ACI-35; Process L3 ACI; s.c.
ACI-35; Process A ACI; i.p.
ACI-35; Process A ACI; s.c.

FIGURE: 15




FIGURE: 16a




FIGURE: 16b



ACI-35-EPFL-017 Proliferation Spleen
Cell proliferation (O.D. 570-690) nm
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Group A: ACI-35 process L3 i.p.
Group B: ACI-35 process L3 s.c.
Group C: ACI-35 process A ACI i.p.
Group D: ACI-35 process A ACI s.c.
Group NS: Naive group no injection
cells alone
ConA 5ug/ml
Tau393-408 [pS396/pS404] 10ug/ml
Tau393-408 [pS396/pS404] 1ug/ml
Tau393-408 10ug/ml
Tau393-408 1ug/ml

FIGURE: 17



ACI-35-EPFL-017 Cytokine production of splenocytes restimulated with Tau393-408 [pS396-pS404] at 10 ug/ml
spots millions of cells
IFN-gamma
IL-4
ACI-35, Process L3 ACI, i.p
ACI-35, Process L3 ACI, s.c.
ACI-35, Process A ACI, i.p.
ACI-35, Process A ACI, s.c
Naive mice, no injection
ACI-35-EPFL-017 Cytokine production of splenocytes restimulated with Tau393-408 [pS396-pS404] at 1 ug/ml
ACI-35-EPFL-017 Cytokine production of splenocytes restimulated with Tau393-408 at 10 ug/ml
ACI-35-EPFL-017 Cytokine production of splenocytes restimulated with Tau393-408 at 10 ug/ml

FIGURE: 18




FIGURE: 19




FIGURE: 20




FIGURE: 21




FIGURE: 22




FIGURE: 23




FIGURE: 24




FIGURE: 25




FIGURE: 26




FIGURE: 27




FIGURE: 28




FIGURE: 29




FIGURE: 30




FIGURE: 31




FIGURE: 32





FIGURE: 33


Mouse # 5
Mouse #6
Mouse #7
Mouse # 8
CD4
CD3



Mean of CD3+/CD4+
Percentage of cells
40.00
36.00
32.00
28.00
24.00
20.00
16.00
12.00
8.00
4.00
0.00
ACI-33 in nude mice
ACI-33 in wild-type mice

Figure 34




Figure 35




Figure 36



ACI-33-JSW-003 total IgG titers after 3 s.c. injections
ACI-33; s.c., nude mice
ACI-33; s.c., wild-type mice
O.D. at 1/100 dilution
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
anti-Tau5-20 [pY18]
anti-Tau5-20
anti-pTau protein
anti-Tau protein

Figure 37